drugset / Trial / NCT03617003

Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)

NCT03617003 ↗

Phase 1 Completed 30 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of a combination of the study drug called WST11 and PDT. Photodynamic therapy (PDT) is a type of ablation therapy (treatment which destroys tumor cells) which has been previously approved for the treatment of patients with other cancers. It works by using a drug that is given through the vein and then is activated in the tumor by light administered during endoscopy, which results in destruction of the cancer cells.

Timeline

Start
2018-08-01
Primary completion
2025-07-15
Completion
2025-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Padeliporfin Other / unclassified 4 mg/kg Intravenous